Biovail 'Still Not Getting the Attention It Deserves' - UBS - trackseekingalpha

Sign Up | Log In | What is SocialPicks?

Biovail 'Still Not Getting the Attention It Deserves' - UBS
May 05, 2009 05:39 PM UTC

trackseekingalpha

Return	Risk
-11.51%	HIGH

Tracked Blogger

Profile & Performance

Subscribe to author

Symbol	Sentiment	Start	Return	Closed
ADP	n/a
PDP	n/a
BVF	n/a
ACAD	n/a

Via Long Investment Ideas from Seeking Alpha:

Biovail Corp.'s (BVF) latest rights acquisition is right on strategy, but whether it proves profitable will likely remain unknown for some time to come, says UBS analyst Marc Goodman.

On Monday, Biovail entered into an agreement with Acadia Pharmaceuticals Inc. (ACAD), to co-develop Acadia's experimental drug for Parkinson's disease psychosis ((PDP)) and Alzheimer's disease psychosis ((ADP)) in the United States and Canada. Acadia will receive an upfront $30-million cash payment from Biovail and is entitled to receive milestone payments totaling more than $300-million.

Read the rest of original post »

Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.